Nexmed (APRI)
Nexmed Capital Expenditures: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
APRI Capital Expenditures Rankings
| Overall | 99th percentile | 1 of 4450 |
| Sector | 99th percentile | 1 of 507 in Healthcare |
| Industry | 97th percentile | 1 of 41 in Drug Manufacturers - Other |
APRI Capital Expenditures Range, Past 5 Years
| Minimum | 0.00 | Jun 2008 |
| Maximum | 0.43M | Dec 2010 |
| Average | 0.0688M |
About Capex
Capital expenditures are a line item from a company's statement of cash flows (click "Learn More" below for details).
Capex (short for capital expenditures) are incurred when a business spends money to purchase fixed assets or to add value to an existing fixed asset. In accounting, a capital expenditures are added to an asset account, thus increasing the value of the asset.
Examples of capital expenditures include the purchase of a new manufacturing plant, investment in server farms for tech companies, or other purchases of assets expected to help the company earn profits in the future.
Unlike other investments like research and development and marketing spending, capital expenditures are not immediately expensed. Rather, property, plant and equipment acquired using capital expenditures are usually expensed over time through the use of depreciation.
Learn More
You may also be interested in these APRI related companies
APRI News
Apricus Biosciences Strengthens Vitaros and Nexact Patent Estate With Two New Patent Allowances
May 25, 1:25PM Benzinga
May 25, 1:25PM Benzinga
Apricus Biosciences (APRI) Granted Request for MycoVa Type C Regulatory Guidance from FDA
May 22, 10:15AM Street Insider
May 22, 10:15AM Street Insider
Apricus Biosciences to Present at the 11th Annual JMP Securities Research Conference
May 14, 9:42AM GlobeNewswire
May 14, 9:42AM GlobeNewswire
Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for the Treatment of Onychomycosis
May 11, 9:55AM GlobeNewswire
May 11, 9:55AM GlobeNewswire
Apricus Biosciences Announces First Quarter 2012 Financial Results Conference Call and Provides Corporate Update
May 08, 9:49AM GlobeNewswire
May 08, 9:49AM GlobeNewswire
Health Canada Grants Apricus Biosciences Pre-NDS Meeting for Femprox for Female Sexual Arousal Disorder
May 07, 10:10AM GlobeNewswire
May 07, 10:10AM GlobeNewswire
Apricus Biosciences Receives Notice of Issuance for First Prevonco(TM) Patent in the United States
Apr 26, 12:01PM Benzinga
Apr 26, 12:01PM Benzinga
$APRI filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3FgE
about 51 days ago by MarketBrief
about 51 days ago by MarketBrief
$APRI New 52 Week Low - Crossed daily lows support. Next support 2.89 from 12/7/2010.
about 66 days ago by TradeIdeasQuant
about 66 days ago by TradeIdeasQuant
Apricus Biosciences (APRI) Gets Paatent Allowance for Dodecy1-2 by EPO
Mar 22, 7:10AM Street Insider
Mar 22, 7:10AM Street Insider
Apricus Biosciences, Inc. (APRI) Transforms From Development Company to Income Generating!
Mar 14, 9:34AM PR Newswire
Mar 14, 9:34AM PR Newswire
Apricus Biosciences' CEO to Present at the 24th Annual ROTH OC Growth Stock Conference
Mar 09, 8:00AM GlobeNewswire
Mar 09, 8:00AM GlobeNewswire
Apricus Biosciences Announces 2011 Year End Financial Results Conference Call
Mar 08, 2:21PM GlobeNewswire
Mar 08, 2:21PM GlobeNewswire
$APRI New 52 Week Low - Crossed daily lows support. Next support 3.05 from 12/9/2010.
about 82 days ago by TradeIdeasQuant
about 82 days ago by TradeIdeasQuant
Looks like $APRI has started to recover a bit, may pick some up on Monday.
about 93 days ago by elysian
about 93 days ago by elysian
Apricus Biosciences Prices $20.0M Public Offering of Common Stock and Warrants
Feb 09, 9:30AM Benzinga
Feb 09, 9:30AM Benzinga
Apricus Biosciences Prices $20.0 Million Public Offering of Common Stock and Warrants
Feb 09, 9:29AM GlobeNewswire
Feb 09, 9:29AM GlobeNewswire
Apricus Biosciences Announces Proposed Public Offering of Common Stock and Warrants
Feb 08, 4:03PM GlobeNewswire
Feb 08, 4:03PM GlobeNewswire
Apricus Biosciences Announces Acquisition of NitroMist(TM) Rights Outside North America
Feb 03, 9:33AM GlobeNewswire
Feb 03, 9:33AM GlobeNewswire
Apricus (APRI), PediatRx Enter Binding Agreement for Granisol Co-Promotion
Jan 27, 8:03AM Street Insider
Jan 27, 8:03AM Street Insider
$APRI enters license agreement with Stellar Pharmaceuticals to market MycoVa in Canada. http://stks.co/1jD0 @adamfeuerstein doh :)
about 149 days ago by TradeHawk
about 149 days ago by TradeHawk
$APRI enters $20m "at the market" equity offering agreement with Ascendiant Capital Markets. http://stks.co/1jC1
about 149 days ago by TradeHawk
about 149 days ago by TradeHawk
$APRI http://stks.co/1fCZ Full correction to Fibo 61.8% and bouncing back, the Golden Cross is very close too #BULLISH
about 157 days ago by gantosj
about 157 days ago by gantosj
$APRI http://stks.co/1Lqt Breaking up the downtrend line & the 200MA with large volume, Bullish sign
about 178 days ago by gantosj
about 178 days ago by gantosj
$APRI Announces New Data Published in the International Journal of Pharmaceutics Confirming Efficiency of NexACT - http://stks.co/buK
about 227 days ago by apricusbio
about 227 days ago by apricusbio
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| APRI | 2.70 | -0.05 | -1.82% | 71.60M |
| APPYD | 0.62 | -0.02 | -3.12% | |
| APPY | 0.62 | -0.02 | -3.12% | 5.971M |
| APP | 0.8505 | -0.01 | -1.68% | 89.86M |
| APOL | 33.12 | +0.61 | +1.88% | 4.170B |
| APOG | 14.97 | -0.02 | -0.13% | 419.46M |
| AON | 47.39 | +0.04 | +0.08% | 15.41B |
| AOL | 27.48 | -0.13 | -0.47% | 2.605B |
| ANX | 0.535 | -0.01 | -0.93% | 25.53M |
| ANW | 5.27 | +0.01 | +0.19% | 243.63M |
